Celebrity Ozempic rumors vs. what GLP-1 drugs actually do

What did @urfavgossip.xoxo actually say?

Honestly? Almost nothing. The transcript is the lyrics to Cyndi Lauper's "Girls Just Want to Have Fun." There are no spoken claims here, no medical statements, no celebrity confessions. The video's entire argument, if you can call it that, is made through hashtags: #ozempic, celebrity names, and body-related tags like #skinny and #fat.

This is a communication strategy in itself. By pairing song lyrics with names like #kimkardashian, #kyliejenner, and #adele alongside #ozempic, the creator is implying without asserting. They get the engagement that comes from celebrity weight-loss speculation without making a single falsifiable claim. It's a tactic worth naming plainly, because 548,700 people watched this and likely walked away with impressions the creator never technically stated.

So this fact-check is really about the claims baked into the hashtag framing, because that framing carries real weight in how audiences understand GLP-1 medications.

Does the science back up the implied claims?

The implied claim, that several named celebrities use semaglutide or similar GLP-1 drugs to stay thin, is unverifiable. None of the celebrities tagged have confirmed use. What the science does confirm is that GLP-1 receptor agonists produce significant weight loss in clinical populations, which is probably why these rumors feel plausible to audiences.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide produced mean weight reduction of up to 20.9% of body weight in adults with obesity. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide at 2.4mg produced about 14.9% mean weight loss versus 2.4% with placebo. These are not trivial numbers. They explain why speculation about celebrity use is culturally sticky, regardless of whether any specific person actually uses these drugs.

What the science does not support is the idea that thinness equals health, which is the aesthetic framework this video's hashtags (#skinny, #thin) operate within. GLP-1 medications are approved for specific clinical indications, not cosmetic weight loss goals.

What did they get wrong, or right?

There is nothing factually wrong here in the traditional sense, because no factual claims were made. But the framing does real harm. Pairing celebrity names with #ozempic as a shorthand for aspirational thinness strips GLP-1 medications of their clinical context entirely.

Semaglutide and tirzepatide are prescribed for type 2 diabetes management and for weight management in people with BMI over 30, or over 27 with a weight-related comorbidity. Using these drugs purely for cosmetic thinness is off-label, and the risk profile does not disappear because a celebrity might be doing it. Common adverse effects include nausea, vomiting, and diarrhea. Rarer but serious concerns include pancreatitis and, in rodent studies, thyroid C-cell tumors, though the latter has not been confirmed in humans (FDA prescribing information, Ozempic 2023).

The video also implicitly conflates being thin with being on Ozempic, and being on Ozempic with being thin for non-medical reasons. That chain of inference does a disservice to patients who use these medications for legitimate metabolic conditions.

What should you actually know?

GLP-1 receptor agonists are serious prescription medications with real clinical evidence behind them and real side effects. They are not a celebrity beauty secret, and speculating about who uses them based on appearance changes does not help anyone make an informed health decision.

If you are considering a GLP-1 medication, the starting point is a clinical evaluation, not a TikTok hashtag. Eligibility criteria exist for medical reasons. A prescriber should review your full health history, including thyroid conditions, personal or family history of medullary thyroid carcinoma, and history of pancreatitis, all of which affect whether these drugs are appropriate for you.

Compounded versions of semaglutide have been widely discussed during shortage periods. Compounded drugs are not FDA-approved and are not equivalent to brand-name Wegovy or Ozempic. The FDA has issued warnings about compounded semaglutide products, including concerns about dosing errors and product quality (FDA, 2023).

The real story here is not which celebrities may or may not be using these drugs. It is that GLP-1 medications represent a genuine shift in how obesity is treated medically, and that shift deserves more serious discussion than a song lyric paired with hashtags.